BRPI0606619A2 - método de análise de oligossacarìdeos, a partir do plasma sangüìneo - Google Patents

método de análise de oligossacarìdeos, a partir do plasma sangüìneo

Info

Publication number
BRPI0606619A2
BRPI0606619A2 BRPI0606619-4A BRPI0606619A BRPI0606619A2 BR PI0606619 A2 BRPI0606619 A2 BR PI0606619A2 BR PI0606619 A BRPI0606619 A BR PI0606619A BR PI0606619 A2 BRPI0606619 A2 BR PI0606619A2
Authority
BR
Brazil
Prior art keywords
analysis
blood plasma
oligosaccharides
molecular weight
low molecular
Prior art date
Application number
BRPI0606619-4A
Other languages
English (en)
Inventor
Pierre Mourier
Christian Viskov
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of BRPI0606619A2 publication Critical patent/BRPI0606619A2/pt
Publication of BRPI0606619B1 publication Critical patent/BRPI0606619B1/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N2030/022—Column chromatography characterised by the kind of separation mechanism
    • G01N2030/027—Liquid chromatography
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
    • G01N2030/8809—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample
    • G01N2030/8813—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
    • G01N2030/8809—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample
    • G01N2030/8813—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials
    • G01N2030/8822—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials involving blood
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
    • G01N2030/8809—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample
    • G01N2030/8813—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials
    • G01N2030/8836—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample biological materials involving saccharides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
    • Y10T436/143333—Saccharide [e.g., DNA, etc.]

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

MéTODO DE ANáLISE DE OLIGOSSACARìDEOS, A PARTIR DO PLASMA SANGüìNEO. A presente invenção refere-se a um método de análise dos oligossacarídeos, que constituem as heparinas de baixo peso molecular e as heparinas de peso molecular muito baixo, a partir do plasma sanguíneo.
BRPI0606619A 2005-01-19 2006-01-18 método de análise de oligossacarídeos, a partir do plasma sangüíneo BRPI0606619B1 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0500554A FR2880951B1 (fr) 2005-01-19 2005-01-19 Methode d'analyse d'oligosaccharides a partir de plasma sanguin
PCT/FR2006/000112 WO2006077317A1 (fr) 2005-01-19 2006-01-18 Methode d'analyse d'oligosaccharides a partir de plasma sanguin

Publications (2)

Publication Number Publication Date
BRPI0606619A2 true BRPI0606619A2 (pt) 2009-07-07
BRPI0606619B1 BRPI0606619B1 (pt) 2016-12-13

Family

ID=35385848

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0606619A BRPI0606619B1 (pt) 2005-01-19 2006-01-18 método de análise de oligossacarídeos, a partir do plasma sangüíneo

Country Status (14)

Country Link
US (1) US7575930B2 (pt)
EP (1) EP1842070B1 (pt)
JP (1) JP5203714B2 (pt)
KR (1) KR20070103387A (pt)
CN (1) CN101107526B (pt)
AR (1) AR051905A1 (pt)
AU (1) AU2006207440B2 (pt)
BR (1) BRPI0606619B1 (pt)
CA (1) CA2591631A1 (pt)
FR (1) FR2880951B1 (pt)
IL (1) IL184417A (pt)
MX (1) MX2007008791A (pt)
RU (1) RU2415436C2 (pt)
WO (1) WO2006077317A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4828795B2 (ja) 2002-03-11 2011-11-30 モメンタ ファーマシューティカルズ インコーポレイテッド 硫酸化多糖類の分析
US7968082B1 (en) 2007-01-26 2011-06-28 Momenta Pharmaceuticals, Inc. Evaluating mixtures of low molecular weight heparins by NMR
US7790466B1 (en) 2007-01-26 2010-09-07 Momenta Pharmaceuticals, Inc. Evaluating mixtures of low molecular weight heparins by chain profiles or chain mapping
US9139876B1 (en) 2007-05-03 2015-09-22 Momenta Pharmacueticals, Inc. Method of analyzing a preparation of a low molecular weight heparin
EP2256138A1 (en) * 2009-05-05 2010-12-01 Sanofi-Aventis Novel acylated 1,6-anhhydro decasaccharide and its use as antithrombotic agent
WO2011090948A1 (en) * 2010-01-19 2011-07-28 Momenta Pharmaceuticals, Inc. Evaluating heparin preparations
WO2012115952A1 (en) 2011-02-21 2012-08-30 Momenta Pharmaceuticals, Inc. Evaluating heparin preparations
WO2020252677A1 (zh) * 2019-06-19 2020-12-24 北京三元食品股份有限公司 乳中游离低聚糖的高通量定量测定方法
CN115112799B (zh) * 2022-06-30 2023-02-28 北京三元食品股份有限公司 一种定性检测母乳中酸性低聚糖的方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8702254D0 (sv) * 1987-05-29 1987-05-29 Kabivitrum Ab Novel heparin derivatives
JPH02227144A (ja) * 1989-02-28 1990-09-10 Asahi Chem Ind Co Ltd 陰イオン交換体及びそれを充填した糖類分離用液体クロマトグラフィー用カラム
US5843786A (en) * 1995-11-28 1998-12-01 Neose Technologies, Inc. Analysis of carbohydrates in biological fluids by high performance liquid chromatography
US6291439B1 (en) * 1998-09-02 2001-09-18 Biomarin Pharmaceuticals Methods for diagnosing atherosclerosis by measuring endogenous heparin and methods for treating atherosclerosis using heparin
US6617316B1 (en) * 1999-10-22 2003-09-09 Aventis Pharma Oligosaccharides, their preparation and pharmaceutical compositions containing them
JP4828795B2 (ja) * 2002-03-11 2011-11-30 モメンタ ファーマシューティカルズ インコーポレイテッド 硫酸化多糖類の分析
US20040265943A1 (en) * 2002-09-23 2004-12-30 Aventis Pharma S.A. Method for quantitatively determining specific groups constituting heparins or low molecular weight heparins
FR2844808B1 (fr) * 2002-09-23 2005-02-25 Aventis Pharma Sa Methode de determination de groupements specifiques constituant les heparines ou les heparines de bas poids moleculaire
CN101747385B (zh) * 2002-09-23 2013-03-06 安万特医药股份有限公司 测定构成肝素的特殊基团的方法

Also Published As

Publication number Publication date
AU2006207440B2 (en) 2011-04-21
RU2007131442A (ru) 2009-02-27
EP1842070A1 (fr) 2007-10-10
FR2880951B1 (fr) 2015-09-18
RU2415436C2 (ru) 2011-03-27
AU2006207440A1 (en) 2006-07-27
KR20070103387A (ko) 2007-10-23
US7575930B2 (en) 2009-08-18
CN101107526B (zh) 2013-08-14
IL184417A (en) 2011-10-31
WO2006077317A1 (fr) 2006-07-27
FR2880951A1 (fr) 2006-07-21
JP2008527390A (ja) 2008-07-24
AR051905A1 (es) 2007-02-14
CN101107526A (zh) 2008-01-16
US20080009069A1 (en) 2008-01-10
EP1842070B1 (fr) 2016-04-13
CA2591631A1 (fr) 2006-07-27
BRPI0606619B1 (pt) 2016-12-13
JP5203714B2 (ja) 2013-06-05
IL184417A0 (en) 2007-10-31
MX2007008791A (es) 2007-09-11

Similar Documents

Publication Publication Date Title
MA30497B1 (fr) Anticorps et immunco-conjugues, et leurs utilisations.
CY1112781T1 (el) 2'-φθορο-2'-δεοξυτετραϋδροουριδινες ως αναστολεις αποαμινασης κυτιδινης
ATE449097T1 (de) Pyridoä2,3-düpyrimidin-2,4-diamin-verbindungen als ptpib-hemmer
BRPI0717822A2 (pt) Composto, processo de fabricação de composto da fórmula i, composição farmacêutica, método de tratamento e/ou profilaxia de doenças que são associadas à modulação de receptores de cb2 e uso de composto.
DE602006006200D1 (de) Antikörper gegen 25-hydroxyvitamin d
MA32934B1 (fr) Combinaisons inhibitrices hsp90
EP2041274A4 (en) PREPARATION OF A SHORT-COATED VOLATILE HYDROCARBON BASED ON GENERALLY MANIPULATED MICROALGEN, CYANOBACTERIA OR BACTERIA
EA200970580A1 (ru) Таннат разагилина
BRPI0818374A8 (pt) Substratos porosos hidrofílicos
EP2033324A4 (en) MEMBRANES, COATINGS AND FILMS AND MANUFACTURING METHOD THEREFOR
EA201170227A1 (ru) Имидазолкарбоксамиды
WO2007098184A3 (en) Methods and compositions for analyte detection
BRPI0720153A8 (pt) Composições e artigos que contêm uma matriz de polímero reticulada e um líquido ativo imobilizado assim como processos de utilização dos mesmos
EP2061808A4 (en) INFLUENZA ANTIBODIES, COMPOSITIONS AND RELATED METHODS
ECSP109968A (es) Depsipéptidos cíclicos
BRPI0713031B8 (pt) composto de di-hidro-piran-2-ona, composição farmacêutica, e uso dos mesmos
BRPI0811933A2 (pt) Avaliação da proporção de gás-óleo sa partir de outras propriedades físicas
BRPI1015043A2 (pt) derivados de diazahomoadamantano e métodos de uso dos mesmos
EP2238451A4 (en) NANOSTRUCTURES, METHOD FOR THE PRODUCTION THEREOF AND USES THEREOF
EP2366691A4 (en) NITROPYRIDINYLETHYLENIMINE COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING THEREOF, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE
CL2007003593A1 (es) Composicion farmaceutica que comprende fluoresceina pura; procedimiento de preparacion de la fluoresceina.
BRPI0606619A2 (pt) método de análise de oligossacarìdeos, a partir do plasma sangüìneo
EP2088140A4 (en) DIHYDRAZIDE COMPOUNDS, MANUFACTURE AND APPLICATIONS THEREOF
BRPI0818409B8 (pt) Método de identificação de uma planta de milho ou germoplasma que apresenta resistência recém-conferida ou resistência aumentada a um membro do sorogrupo 2 de fijivirus, ou suscetibilidade a um membro do sorogrupo 2 de fijivírus, método de produção de uma planta de milho apresentando resistência recém-conferida ou resistência aumentada a um membro do sorogrupo 2 de fijivírus e método de seleção de pelo menos uma planta de milho através de seleção assistida por marcador de um lócus de traço quantitativo associado com a resistência recém-conferida ou resistência aumentada a um membro do sorogrupo 2 de fijivírus
WO2007035872A3 (en) Tdf-related compounds and analogs thereof

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06H Technical and formal requirements: requirement cancelled [chapter 6.8 patent gazette]

Free format text: REF. A RPI NO 2150 DE 20/03/2012. ANULACAO DA EXIGENCIA 6.6 POR TER SIDO INDEVIDA. REQUERENTE NAO APRESENTOU RESPOSTA A EXIGENCIA CONFORME DISPOE A RESOLUCAO 207 DE 24/04/2009, ENTRETANTO, A RESPOSTA CONSTA NO FORMULARIO DE DEPOSITO.

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 13/12/2016, OBSERVADAS AS CONDICOES LEGAIS.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 15A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2614 DE 09-02-2021 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.